Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With<i>EGFR</i>-Mutated Advanced Non–Small Cell Lung Cancer

Pedro Nazareth Aguiar, Gilberto Lopes|JAMA Oncology|2018

Cited by 121